A detailed history of D. E. Shaw & Co., Inc. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 204,892 shares of XENE stock, worth $7.97 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
204,892
Holding current value
$7.97 Million
% of portfolio
0.01%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$36.12 - $43.96 $1.56 Million - $1.9 Million
43,170 Added 26.69%
204,892 $8.06 Million
Q2 2024

Aug 14, 2024

SELL
$36.25 - $43.75 $1.33 Million - $1.61 Million
-36,804 Reduced 18.54%
161,722 $6.31 Million
Q1 2024

May 15, 2024

BUY
$42.66 - $50.04 $4.88 Million - $5.72 Million
114,373 Added 135.91%
198,526 $8.55 Million
Q4 2023

Feb 14, 2024

BUY
$28.7 - $46.46 $1.25 Million - $2.03 Million
43,606 Added 107.54%
84,153 $3.88 Million
Q3 2023

Nov 14, 2023

SELL
$34.16 - $39.73 $1.99 Million - $2.31 Million
-58,198 Reduced 58.94%
40,547 $1.39 Million
Q2 2023

Aug 14, 2023

SELL
$34.84 - $43.54 $3.76 Million - $4.7 Million
-107,927 Reduced 52.22%
98,745 $3.8 Million
Q1 2023

May 15, 2023

SELL
$33.46 - $40.35 $5.14 Million - $6.2 Million
-153,749 Reduced 42.66%
206,672 $7.4 Million
Q4 2022

Feb 14, 2023

SELL
$33.06 - $39.43 $1.62 Million - $1.94 Million
-49,142 Reduced 12.0%
360,421 $14.2 Million
Q3 2022

Nov 14, 2022

BUY
$30.79 - $39.82 $2.56 Million - $3.31 Million
83,021 Added 25.42%
409,563 $14.8 Million
Q2 2022

Aug 15, 2022

SELL
$25.44 - $35.16 $101,378 - $140,112
-3,985 Reduced 1.21%
326,542 $9.93 Million
Q1 2022

May 16, 2022

SELL
$25.09 - $33.13 $3.63 Million - $4.79 Million
-144,613 Reduced 30.44%
330,527 $10.1 Million
Q4 2021

Feb 14, 2022

BUY
$15.6 - $35.4 $5.09 Million - $11.5 Million
326,261 Added 219.15%
475,140 $14.8 Million
Q3 2021

Nov 15, 2021

SELL
$14.86 - $19.45 $225,753 - $295,484
-15,192 Reduced 9.26%
148,879 $2.28 Million
Q2 2021

Aug 16, 2021

SELL
$16.81 - $20.0 $183,632 - $218,480
-10,924 Reduced 6.24%
164,071 $3.06 Million
Q1 2021

May 17, 2021

SELL
$13.65 - $21.31 $119,369 - $186,355
-8,745 Reduced 4.76%
174,995 $3.13 Million
Q4 2020

Feb 16, 2021

SELL
$9.49 - $16.04 $81,357 - $137,510
-8,573 Reduced 4.46%
183,740 $2.83 Million
Q3 2020

Nov 16, 2020

SELL
$10.82 - $13.35 $187,240 - $231,021
-17,305 Reduced 8.26%
192,313 $2.13 Million
Q2 2020

Aug 14, 2020

BUY
$10.21 - $14.9 $685,193 - $999,939
67,110 Added 47.09%
209,618 $2.63 Million
Q1 2020

May 15, 2020

BUY
$8.08 - $17.57 $772,698 - $1.68 Million
95,631 Added 204.0%
142,508 $1.62 Million
Q4 2019

Feb 14, 2020

BUY
$8.11 - $14.65 $129,589 - $234,092
15,979 Added 51.72%
46,877 $615,000
Q3 2019

Nov 14, 2019

BUY
$8.74 - $10.51 $1,153 - $1,387
132 Added 0.43%
30,898 $278,000
Q2 2019

Aug 14, 2019

SELL
$8.51 - $10.75 $211,609 - $267,309
-24,866 Reduced 44.7%
30,766 $303,000
Q1 2019

May 15, 2019

SELL
$6.39 - $10.42 $483,007 - $787,626
-75,588 Reduced 57.6%
55,632 $565,000
Q4 2018

Feb 14, 2019

BUY
$5.61 - $12.62 $736,144 - $1.66 Million
131,220 New
131,220 $828,000

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.42B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.